Grade 3 IDH1-mutant glioma

Clinical trials for Grade 3 IDH1-mutant glioma explained in plain language.

Never miss a new study

Get alerted when new Grade 3 IDH1-mutant glioma trials appear

Sign up with your email to follow new studies for Grade 3 IDH1-mutant glioma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for brain tumor patients when standard drug fails

Disease control Not yet recruiting

This study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…

Matched conditions: GRADE 3 IDH1-MUTANT GLIOMA

Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC

Grade 3 IDH1-mutant glioma

Get alerted when new Grade 3 IDH1-mutant glioma trials appear

New hope for brain tumor patients when standard drug fails